Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

40.71 -0.09 (-0.22%)
Streaming Delayed Price Updated: 2:59 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Earnings Scheduled For November 4, 2025
 
Via Benzinga
Preview: Exelixis's Earnings
 
Via Benzinga
17 Analysts Have This To Say About Exelixis
 
Via Benzinga
What's Driving the Market Sentiment Around Exelixis Inc?
 
Via Benzinga
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity
Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector. 
Via Chartmill
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Exelixis, Inc.
Via Business Wire
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing In October
 
Via Benzinga
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
From Exelixis, Inc.
Via Business Wire
The Ultimate Biotech Stock to Buy With $50 Right Now
This innovative drugmaker still has plenty of upside potential. 
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening
Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock
Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector. 
Via Chartmill
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Both should have significant catalysts by the end of the decade. 
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals
EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy
Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.